Daily Anesthesiology Research Analysis
Analyzed 116 papers and selected 3 impactful papers.
Summary
Three impactful anesthesiology studies stand out today: a multinational propensity-matched cohort links sevoflurane (vs propofol) anesthesia to higher long-term depression risk; a randomized trial shows driving pressure–guided PEEP reduces intraoperative lung de-aeration in robot-assisted prostate surgery; and a proof-of-concept RCT finds oliceridine pretreatment markedly reduces etomidate-induced myoclonus. Together, they inform anesthetic selection, individualized ventilation, and mitigation of induction side effects.
Research Themes
- Anesthetic choice and long-term neuropsychiatric outcomes
- Individualized intraoperative ventilation based on driving pressure
- Biased mu-opioid agonists to mitigate induction side effects
Selected Articles
1. Long-term risk of depression after sevoflurane versus propofol anesthesia: a global propensity score-matched cohort study.
In a 37,936-patient propensity-matched cohort with a new-user design and ≥1-year latency, sevoflurane anesthesia was associated with a higher risk of new-onset depression than propofol (aHR 1.51), consistent across subgroups. A graded increase in risk with repeated sevoflurane exposures supports biological plausibility.
Impact: This large, methodologically rigorous study links anesthetic choice to long-term neuropsychiatric outcomes and demonstrates a dose-response gradient, potentially informing patient counseling and agent selection.
Clinical Implications: When feasible, propofol may be preferred for patients at higher baseline risk for depression or where long-term neuropsychiatric sequelae are a concern. Shared decision-making should include discussion of potential long-term risks, while acknowledging observational limitations.
Key Findings
- Sevoflurane was associated with higher new-onset depression risk vs propofol (aHR 1.51; 95% CI 1.41–1.61).
- The association persisted across severity strata and surgical subgroups.
- A biologic gradient was observed: ≥2 sevoflurane exposures increased risk further (aHR 1.75).
- New-user design with ≥1-year latency minimized reverse causality and protopathic bias.
Methodological Strengths
- Large multinational propensity score-matched cohort with a new-user design and ≥1-year washout.
- Demonstration of dose-response (biologic gradient) and extensive covariate balance across >100 variables.
Limitations
- Observational design susceptible to residual confounding and misclassification.
- Outcome ascertainment relies on EHR coding without standardized psychiatric assessment.
Future Directions: Prospective mechanistic and randomized perioperative strategies (e.g., anesthetic selection pathways, neuroinflammation biomarkers) should test causality and mitigation approaches.
Preclinical studies indicate that volatile anesthetics such as sevoflurane induce neuroinflammation and oxidative stress-mechanisms implicated in the pathophysiology of depression-whereas propofol exhibits neuroprotective properties. However, whether these pharmacological differences translate into distinct long-term psychiatric outcomes in humans remains unclear. We conducted a multinational propensity score-matched cohort study using the TriNetX Global Federated Network (2005-2024) to determine whether sevoflurane anesthesia is associated with a higher risk of long-term depression compared with propofol. To isolate the effect of anesthetic choice, we applied a new-user design with a one-year latency washout, excluding patients with preexisting depression or antidepressant use. The primary outcome was new-onset depression diagnosed more than one year after anesthesia. The matched cohort included 37,936 patients balanced across more than 100 covariates. Sevoflurane exposure was associated with a higher risk of new-onset depression compared with propofol (adjusted hazard ratio [aHR], 1.51; 95% CI, 1.41-1.61). The association remained consistent across severity strata (aHR, 1.51 for moderate-to-severe depression) and surgical subgroups. Notably, we observed a graded dose-response relationship, where repeated sevoflurane exposures conferred progressively higher risk (aHR, 1.75 for ≥2 exposures), consistent with a biologic gradient. In this large multinational cohort, sevoflurane use was associated with a higher long-term risk of incident depression compared with propofol. These findings align with preclinical evidence of anesthetic-related neuroinflammatory mechanisms and indicate that anesthetic selection may have implications for long-term neuropsychiatric risk. Further mechanistic and prospective studies are warranted.
2. Driving pressure guided ventilation in robot-assisted laparoscopic surgery with steep Trendelenburg position: a randomized controlled study.
In RALP patients, DP-guided individualized PEEP (median 8 cmH2O) lowered driving pressures, reduced lung ultrasound aeration loss, and improved intraoperative oxygenation compared with fixed PEEP 5 cmH2O, without differences in PPCs or length of stay.
Impact: Provides randomized evidence that DP minimization can guide PEEP titration to reduce intraoperative de-aeration in steep Trendelenburg settings, supporting physiologically individualized ventilation.
Clinical Implications: DP-guided PEEP titration is feasible and improves lung aeration and oxygenation during RALP; adoption may be considered for high-risk de-aeration scenarios, while recognizing lack of demonstrated PPC reduction.
Key Findings
- DP-guided PEEP (median 8 cmH2O) vs fixed 5 cmH2O reduced driving pressure during Trendelenburg (19.0±3.4 vs 21.3±4.7 cmH2O; P=0.035).
- Lower modified lung ultrasound scores at end-Trendelenburg and in recovery (median difference −2.0; P=0.032; recovery P<0.001).
- Higher intraoperative PaO2 with DP-guided PEEP (154.6±33.1 vs 133.3±34.7 mmHg; P=0.015); PPCs and LOS unchanged.
Methodological Strengths
- Randomized controlled design with physiologic primary endpoint (lung ultrasound score).
- Objective titration protocol (decremental PEEP to minimize driving pressure).
Limitations
- Single-center trial with modest sample size (n=63 analyzed), potentially underpowered for PPCs.
- Short-term outcomes; no long-term respiratory follow-up.
Future Directions: Multicenter RCTs powered for PPCs and longer-term respiratory outcomes; application to other procedures and obesity cohorts; integration with individualized FiO2 and recruitment strategies.
BACKGROUND: Robot-assisted laparoscopic prostatectomy (RALP) with pneumoperitoneum and steep Trendelenburg positioning impairs ventilation and increases the risk of postoperative pulmonary complications (PPCs). Although positive end-expiratory pressure (PEEP) may reduce atelectasis, the optimal levels remain unclear. This study evaluated the effects of driving pressure (DP)-guided PEEP titration during RALP. METHODS: This single-center, randomized controlled trial enrolled adults undergoing RALP (American Society of Anesthesiologists < 3, without pulmonary disease) for either DP minimization-guided individualized PEEP (DP group) or fixed 5 cmH2O PEEP (control). DP was calculated as plateau pressure minus PEEP, with individualized PEEP determined using decremental titration. Atelectasis was quantified using modified lung ultrasound (LUS) score, incorporating B-lines and consolidations. Primary outcome was LUS score at end-Trendelenburg. Secondary outcomes included oxygenation and PPCs. RESULTS: Of 101 assessed, 63 completed analysis. The DP group (n=31) received higher individualized PEEP (median 8.0 cmH2O) during Trendelenburg than controls (5.0 cmH2O, n=32). In the DP group, mean DP was lower during Trendelenburg (19.0 ± 3.4 vs. 21.3 ± 4.7 cmH2O, P=0.035) and LUS score was significantly lower at the end-Trendelenburg (median [1Q, 3Q]: 9.0 [8.0, 11.5] vs. 11.0 [9.0, 13.0]; median difference, -2.0 [95% CI, -3.0 to 0.0]; P=0.032) and recovery (9.0 vs. 13.5, P<0.001). Intraoperative PaO2 during Trendelenburg was higher in the DP group (154.6 ± 33.1 vs. 133.3 ± 34.7 mmHg, P=0.015). PPCs and hospital stay were comparable between groups. CONCLUSIONS: DP-guided PEEP titration during RALP reduced lung de-aeration burden assessed by modified LUS score, though benefits did not translate to reduced PPCs.
3. Effect of Oliceridine Pretreatment on Etomidate-Induced Myoclonus: A Proof-of-Concept Randomized Trial.
Pretreatment with oliceridine 0.03 mg/kg significantly reduced the incidence (and severity) of etomidate-induced myoclonus compared with saline, with stable perioperative hemodynamics and a signal for lower POD1 pain scores.
Impact: Introduces a biased μ-opioid agonist strategy to mitigate a common induction side effect without compromising hemodynamics, potentially improving patient comfort and induction quality.
Clinical Implications: Oliceridine pretreatment may be considered to reduce etomidate-induced myoclonus when hemodynamic stability is prioritized; broader validation is needed before routine adoption.
Key Findings
- Double-blind RCT (n=93 completed) showed markedly lower myoclonus incidence with oliceridine vs saline (10.9% vs 57.4%).
- Myoclonus severity was reduced with oliceridine; perioperative hemodynamics remained stable.
- Postoperative day 1 pain scores were lower with oliceridine, though interpretation is cautious.
Methodological Strengths
- Randomized, double-blind design with active perioperative monitoring.
- Clinically meaningful primary endpoint (myoclonus incidence) and standardized dosing/timing.
Limitations
- Single-center proof-of-concept with modest sample size; generalizability remains uncertain.
- Abstract-truncated reporting limits full appraisal of secondary outcomes and adverse events.
Future Directions: Multicenter trials across ASA classes and higher-risk populations; head-to-head comparisons with alternative anti-myoclonus strategies and dose–response optimization.
PURPOSE: Etomidate offers hemodynamic stability for anesthesia induction but frequently causes myoclonus. This study evaluated oliceridine, a G-protein biased μ-opioid receptor agonist, for prevention of etomidate-induced myoclonus. PATIENTS AND METHODS: In this double-blind, randomized trial, patients scheduled for elective general anesthesia were allocated to receive either intravenous oliceridine 0.03 mg/kg (Group O) or an equivalent volume of normal saline (Group NC) 5 minutes before anesthesia induction with 0.3 mg/kg etomidate administered over 30-60s. The primary outcome was the incidence of myoclonus within 2 minutes after etomidate administration. Secondary outcome was the severity of myoclonus. Perioperative hemodynamic variables, the incidence of adverse events and postoperative pain intensity (assessed using the Numerical Rating Scale) were recorded. RESULTS: Of 93 patients who completed the study, Group O showed lower myoclonus incidence (10.9% vs 57.4%; CONCLUSION: In this single-center proof-of-concept randomized trial of ASA I-II patients, pretreatment with oliceridine (0.03 mg/kg) before etomidate induction reduced the incidence of etomidate-induced myoclonus. The statistically lower postoperative day 1 pain scores in the oliceridine group should be interpreted cautiously, and these findings warrant confirmation in larger multicenter trials involving broader patient populations.